Close Menu

financial guidance

The $500 million sale of its Illumination and Detection Solutions business will free up capital that can be reinvested in the firm's Human Health and Environmental Health businesses.

23andMe has sent a letter to the heads of the FDA and NIH asking for help in developing broadly applicable standards and guidelines for providing genetic test results and risk estimates.

Already a pioneer in incorporating pharmacogenetic testing into its PBM programs, Medco's decision to buy DNA Direct signals its intent to be a "one-stop shop" for payors and employers interested in using genetically guided medicine to make healthcare more efficient and lower costs.

Caliper Life Sciences' expected Q4 2009 revenues of $37.6 million exceeds the company's previous guidance of $33 to $35 million.


According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.